1. US Food and Drug Administration.Guidance for industry— pharmacogenomic data submissions. Available at: http://www.fda.gov/cder/guidance/6400fnl.pdf. Accessed October 25, 2006.
2. US Food and Drug Administration.Table of valid genomic biomarkers in the context of approved drug labels. Available at: http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm. Accessed October 25, 2006.
3. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers.Pharmacogenomics. 2006;7:773.
4. Clinton P, Wechsler J. What Ever Happened to Critical Path.Pharmaceutical Executive. 2006; Available at: http://www.pharmexec. com/pharmexec/article/article Detail.jsp?id=282481&pageID=6. Accessed November 12, 2006.
5. US Food and Drug Administration.Predictive Safety Testing Consortium. Available at: http://www.fda.gov/oc/initiatives/criticalpath/projectsummary/consortium.html. Accessed October 25, 2006.